Loading...
First Round of Abstract Submission Ends: Nov 30, 2026
Extended Early Bird Ends: Apr 28, 2026

Keynote Speakers

Dr. Karla Neves
University of Strathclyde, UK
Title: Decoding Vascular Injury in Cancer Therapy: A Molecular and Cellular Perspective
Dr Karla Neves is a basic-scientist and Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, in Glasgow UK, with a multidisciplinary background spanning nursing, pharmacology, and biomedical science. After completing her BSc in Nursing in Brazil, she pursued an MSc and PhD in Pharmacology at the University of Sao Paulo, followed by postdoctoral research at the University of Glasgow, UK, where she developed expertise in vascular biology and cardiovascular pharmacology. Her research focuses on the mechanisms of vascular dysfunction, with particular emphasis on cardiovascular toxicity associated with cancer therapies, endothelial signalling, and translational vascular medicine. She has contributed to over 50 peer-reviewed publications and collaborates internationally across the UK, Brazil, and China. Dr Neves is also actively involved in teaching, research supervision, and public engagement, and plays a leading role in outreach and widening participation initiatives in STEM.
Dr. Bing Li
Lanzhou Institute of Husbandry and Pharmaceutical Sciences, China
Title: To be confirmed.
Will update soon.
Prof. Zhu Yi Zhun
Macau University of Science and Technology, Macau SAR
Title: Molecular pharmacology and new target drug discovery: bench to bedside
Will update soon.
Dr. Samuel CONSTANT
Chief Executive Officer, Epithelix Sàrl, Switzerland
Title: Immunocompetent in vitro airway models as decision-making tools for pharmacology and toxicology research
Dr. Samuel Constant is co-founder and Chief Executive Officer of Epithelix. He is responsible for the global management and strategic direction of the company’s Swiss and French sites. Samuel has co-authored more than 150 publications and has received 18 awards for scientific achievements, technological innovation, and business development.
Prof. Miroslav Radenković
University of Belgrade, Serbia
Title: Biopharmaceuticals – Current Standing
Miroslav Radenković, MD, MS, PhD, a full-time professor at the Department of Pharmacology, Clinical Pharmacology and Toxicology, graduated from the Faculty of Medicine – University of Belgrade (FMUB) in 1995, and from 1996 he is working at the FMUB. He received an MS from pharmacology, board certified in Clinical Pharmacology, PhD from Medical Sciences, and a sub-specialization degree in Clinical Pharmacology - Pharmacotherapy in 1999, 2000, 2004, and 2016 respectively, from the FMUB, as well as Bioethics MS in 2021 from the Clarkson University, NYC, USA. From 2002 Dr. Radenković officially participated in several scientific projects supported by the Ministry of Science – Serbia; the Austrian Science Fund; COST Action; as well as the NIH Fogarty International Center Project, USA. Dr. Radenković is a member of the Ethics Board of Serbia and a Chair Department.
Dr. Sasidharan Sreenivasan
Universiti Sains Malaysia, Malaysia
Title: Will Update Soon
Sasidharan Sreenivasan obtained his Ph. D. in 2007 from Universiti Sains Malaysia, Malaysia. He was served as the Deputy Director at Institute for Research in Molecular Medicine, Universiti Sains Malaysia from 2019 till 2021. He has over 230 publications with a total impact factor of > 250 (With more than 700 citations in Scopus and h-Index = 42), published 16 chapters in book with international publishers, as well as Keynote, Invited Speaker and Chair of International & National Congresses. Has been serving as an Editor, Editorial Board Member, reviewer of international journals and evaluator for national and international grants. He has been recognized nationally and internationally as an expert in Pharmacognosy, Pharmacology, and anticancer studies, especially those that involve the pharmacological activity of medicinal plants. He was selected as a Top Research Scientists Malaysia (TRSM) by the Academy of Sciences Malaysia (ASM) in the year of 2022. In 2020, 2021, 2022, 2023, and 2024 he was figured among the top two percent (2%) scientists in a global list compiled by the prestigious Standford University from the United States of America. He reviewed more than 574 (Publoans) manuscripts for international journals. In 2019, he was placed in the top 1% of reviewers in Pharmacology and Toxicology, Clinical Medicine, and Cross-Field on Publons global reviewer database, United States of America. His research interests include medicinal plants, miRNA, nanoparticle and their role in Health and Disease Management, particularly natural products and nanoparticles (Green Carbon Dots) based antimicrobial, antioxidant, and anticancer agent development and toxicity study in cellular, genomic and animal model.
Dr. Mariana PINTEALA
Petru Poni Institute of Macromolecular Chemistry, Romania
Title: Will Update Soon
Will Update Soon
Dr. Ke Ding
Jinan University, China
Title: Will Update Soon
Will Update Soon